Scarica l'app Stockscreener
225.00
14.21%
28.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$197.00
Aprire:
$199
Volume 24 ore:
28.75M
Relative Volume:
1.50
Capitalizzazione di mercato:
$89.83B
Reddito:
$2.23B
Utile/perdita netta:
$-3.19B
Rapporto P/E:
-27.62
EPS:
-8.1462
Flusso di cassa netto:
$-1.60B
1 W Prestazione:
+18.41%
1M Prestazione:
+65.92%
6M Prestazione:
+338.77%
1 anno Prestazione:
+717.29%
Intervallo 1D:
$197.17
$225.00
Intervallo di 1 settimana:
$182.50
$225.00
Portata 52W:
$22.28
$225.00
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-30 | Downgrade | Citigroup | Neutral → Sell |
| 2026-09-03 | Downgrade | Rothschild & Co Redburn | Neutral → Sell |
| 2026-08-28 | Aggiornamento | Argus | Hold → Buy |
| 2026-08-25 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2026-08-19 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2026-08-19 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock? - Zacks Investment Research
Is Invesco S&P 500 Equal Weight ETF (RSP) a Strong ETF Right Now? - Zacks Investment Research
Form 4 Moderna Inc For: 7 October By Investing.com - Investing.com Canada
Moderna (MRNA) CFO has 704 shares withheld for taxes after converting a stock grant. - Stock Titan
Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity? - Zacks Investment Research
Moderna (MRNA) COO Juan Andres reports direct ownership of 125,000 common shares. - stocktitan.net
Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026 - GlobeNewswire Inc.
Moderna (MRNA) Stock Dips While Market Gains: Key Facts - Zacks Investment Research
Moderna Inc (MRNA) Stock News & Articles - 24/7 Wall St.
Prediction: Moderna Stock Will Soar 100% by 2030 - The Motley Fool
Stock Market Midday, Sept. 30: Markets Rise on Softer Inflation Data, Investors Await Micron Earnings - The Motley Fool
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now? - Zacks Investment Research
Up Over 550% in 2026, Is It Too Late to Buy Moderna Stock? - The Motley Fool
Moderna stock at USD 198.88 on September 25, 2026, up 2.08 percent - AD HOC NEWS
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate - Zacks Investment Research
3 Bullish Setups for the Week Ahead - Zacks Investment Research
Moderna, Inc.Common Stock (NQ: MRNA - The Chronicle-Journal
Moderna, Inc.Common Stock (NQ: MRNA - The Chronicle-Journal
Moderna (MRNA) insider exercises options, sells 80K shares - stocktitan.net
Moderna, Inc.Common Stock (NQ: MRNA - The Chronicle-Journal
Another multimillion stock sale lined up for 2026 at Moderna (NASDAQ: MRNA) - stocktitan.net
Moderna (MRNA) CFO sells 34,836 shares under pre-set plan - stocktitan.net
Insider at Moderna (NASDAQ: MRNA) plans multimillion-dollar stock sale for 2026 - stocktitan.net
Top Biotech Stocks To Watch TodaySeptember 13th - MarketBeat
Promising Biotech Stocks To Keep An Eye OnSeptember 12th - MarketBeat
California State Teachers Retirement System Buys 27,274,128 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know - Yahoo Finance
Moderna stock gains after a 6.7 percent jump - ad-hoc-news.de
Healthcare Stocks To Keep An Eye OnSeptember 11th - MarketBeat
Moderna Inc Stock (MRNA) Moved Up by 8.63% on Sep 11: A Full Analysis - TradingKey
MRNA Looks 517.6% Overvalued on GF Value™ as Price-to-Sales Soars Amid Losses - GuruFocus
MRNA Stock Climbs As Analysts Back Oncology And Vaccine Push - StocksToTrade
MRNA Stock Climbs As Oncology Catalysts And Upgrades Pile Up - timothysykes.com
Moderna (NASDAQ:MRNA) Shares Up 6.7%Should You Buy? - MarketBeat
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know - The Globe and Mail
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know - tradingview.com
Best Biotech Stocks To Watch NowSeptember 11th - MarketBeat
Moderna climbs 8% as volatile trading continues (MRNA:NASDAQ) - Seeking Alpha
Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat - Yahoo Finance
Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat - 24/7 Wall St.
Why Is Techne (TECH) Down 0.1% Since Last Earnings Report? - Zacks Investment Research
What to Know About the 2026–2027 COVID-19 Vaccines - Verywell Health
Frequency Electronics, ACV Auctions, HP And Other Big Stocks Moving Higher On Friday - benzinga.com
Why is Moderna stock rallying today? By Investing.com - Investing.com Canada
Why Is the Market Watching Moderna (MRNA)? - Kalkine Media
Amundi Reduces Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
Rep. Maria Elvira Salazar Sells Moderna, Inc. (NASDAQ:MRNA) Stock - MarketBeat
Rep. Maria Elvira Salazar Acquires Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Congresswoman Bets on Elon Musk, Warren Buffett: Here’s the Latest Stock Transactions - TradingView
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Moderna Inc Azioni (MRNA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hoge Stephen | Officer |
Sep 15 '26 |
Proposed Sale |
146.07 |
40,281 |
5,883,709 |
0 |
| Hoge Stephen | President |
Sep 15 '26 |
Sale |
146.07 |
40,281 |
5,883,846 |
1,562,029 |
| Hoge Stephen | President |
Sep 15 '26 |
Option Exercise |
12.21 |
76,452 |
933,479 |
1,602,310 |
| Hoge Stephen | Officer |
Sep 14 '26 |
Proposed Sale |
144.13 |
40,294 |
5,807,746 |
0 |
| Hoge Stephen | President |
Sep 14 '26 |
Sale |
144.13 |
40,294 |
5,807,574 |
1,525,858 |
| Mock James M | Chief Financial Officer |
Sep 10 '26 |
Sale |
134.49 |
34,836 |
4,685,094 |
59,375 |
| Mock James M | Chief Financial Officer |
Sep 10 '26 |
Option Exercise |
30.96 |
19,836 |
614,123 |
94,211 |
| Mock James M | Officer |
Sep 10 '26 |
Proposed Sale |
134.49 |
34,836 |
4,685,094 |
0 |
| Klinger Shannon Thyme | Chief Legal Officer |
Sep 01 '26 |
Option Exercise |
30.96 |
3,471 |
107,462 |
77,600 |
| Klinger Shannon Thyme | Chief Legal Officer |
Sep 01 '26 |
Sale |
139.95 |
3,471 |
485,766 |
74,129 |
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):